Protara Therapeutics Inc (TARA)
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its lead candidate is TARA-002, an investigational cell therapy being studied in phase II trials for non-muscle invasive bladder cancer and lymphatic malformations. The company is also advancing intravenous choline chloride, an investigational phospholipid substrate replacement therapy intended for patients receiving parenteral nutrition and fluids. Protara Therapeutics is headquartered in New York, New York, and its common stock trades on the NASDAQ under the ticker TARA.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TARA
|
$3.69
|
-9.8% Downside
|
Fair
|
$26.57
|
549.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-3.6x
|
1.3x
|
—
|
228.8 M
|
55.786 M
|
1.3%
|
87.5%
|
10.1
|
—
|
99.6%
|
